TL;DR: Tesamorelin is the strongest GH peptide for visceral fat reduction — FDA-approved with Phase 3 trial data showing 15-18% reduction. CJC-1295/ipamorelin is the most popular stack for general anti-aging — clean GH pulses, minimal side effects, good for sleep, recovery, and body composition. For maximum effect, combine tesamorelin with ipamorelin to hit both GHRH and ghrelin pathways simultaneously.
What Are These Peptides?
Tesamorelin (brand names: Egrifta, Egrifta WR) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is the only GH peptide with FDA approval, indicated for reducing excess abdominal fat in HIV-associated lipodystrophy. It stimulates the pituitary gland to release growth hormone in strong, natural pulses.
CJC-1295 (without DAC) is a synthetic GHRH analog — the same class as tesamorelin but a different molecular structure. "Without DAC" (Drug Affinity Complex) refers to the shorter-acting version (also called Mod GRF 1-29) that produces GH pulses lasting 30-60 minutes rather than the sustained elevation of CJC-1295 with DAC.
Ipamorelin is a growth hormone-releasing peptide (GHRP) — a ghrelin receptor agonist. It stimulates GH release through a completely different receptor pathway than GHRH analogs. Ipamorelin is known for producing clean GH pulses without the cortisol, prolactin, or appetite spikes seen with older GHRPs like GHRP-6.
The CJC-1295/ipamorelin stack combines both pathways — GHRH (CJC-1295) tells the pituitary to release GH, while the ghrelin mimetic (ipamorelin) amplifies the signal. This dual approach produces stronger GH pulses than either peptide alone.
How They Work
Tesamorelin: Potent GHRH Stimulation
- Binds to GHRH receptors on the anterior pituitary to trigger strong, pulsatile GH release
- Produces physiologically normal GH release patterns (unlike exogenous HGH which creates flat, supraphysiologic levels)
- Specifically targets visceral adipose tissue through GH-mediated lipolysis
- Reduces hepatic fat content significantly
- Daily subcutaneous injection (1-2 mg)
CJC-1295 (no DAC): Moderate GHRH Stimulation
- Binds to the same GHRH receptors as tesamorelin but with different pharmacokinetics
- Shorter-acting — produces GH pulses lasting 30-60 minutes
- Designed to be combined with a GHRP for synergistic GH release
- Typically injected 1-3 times daily
Ipamorelin: Clean Ghrelin Receptor Activation
- Activates the ghrelin (GHS-R) receptor on the pituitary — a separate pathway from GHRH
- Produces selective GH release without increasing cortisol, prolactin, or appetite
- The "cleanest" GH secretagogue in terms of side effect profile
- Works synergistically with GHRH analogs — amplifies the GH pulse when combined
Side-by-Side Comparison
| Factor | Tesamorelin | CJC-1295/Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog + ghrelin mimetic |
| Receptor target | GHRH receptor | GHRH receptor + GHS-R (ghrelin) |
| GH release pattern | Strong pulsatile | Moderate-strong pulsatile |
| Primary use | Visceral fat reduction | Anti-aging, sleep, recovery, body comp |
| Evidence level | Strong (FDA-approved, Phase 3 trials) | Moderate (clinical studies, not FDA-approved) |
| Visceral fat data | 15-18% reduction in 26 weeks (proven) | Indirect (via GH elevation, not specifically studied) |
| Dosing | 1-2 mg once daily | CJC: 100 mcg + Ipa: 100-200 mcg, 1-3x daily |
| Timing | Bedtime, empty stomach | Bedtime, empty stomach (or split AM/PM) |
| Sleep improvement | Yes (via nighttime GH pulse) | Yes (commonly reported first benefit) |
| Side effects | Injection site reactions, joint pain, edema | Minimal — headache, flushing (uncommon) |
| Cortisol impact | None | None (ipamorelin is selective) |
| Appetite impact | None | None (unlike GHRP-6) |
| FDA status | Approved (Egrifta/Egrifta WR) | Not approved (research peptide) |
| Cost | Higher (prescription or research) | Moderate (research peptide) |
Clinical Evidence
Tesamorelin
Tesamorelin has the strongest clinical evidence of any GH peptide:
- Phase 3 trials (LIPO-008, LIPO-011): 15-18% reduction in visceral adipose tissue (VAT) over 26 weeks. 69% of treated patients achieved clinically significant VAT reduction vs 33% on placebo.
- Body composition: Increased lean body mass with reduced waist circumference (~2-3 cm over 26 weeks).
- Liver fat: Significant reductions in hepatic fat content with improved liver enzymes.
- Cognitive function: Friedman et al. (2013) found tesamorelin improved executive function and verbal memory in older adults with mild cognitive impairment over 20 weeks.
- 52-week data: LIPO-011 showed maintained fat reduction through 52 weeks of continuous use.
CJC-1295/Ipamorelin
Evidence is less extensive but supportive:
- CJC-1295: Clinical studies demonstrated sustained GH and IGF-1 elevation with dose-dependent responses. The DAC version showed prolonged GH elevation; the no-DAC version produces cleaner, more physiologic pulses.
- Ipamorelin: Phase 2 studies showed selective GH release without cortisol or prolactin increases — confirming its "clean" profile. Studied for post-operative ileus recovery.
- The stack: No large-scale trials of the combination, but the pharmacologic rationale (dual-pathway GH stimulation) is well-established and widely used in clinical peptide therapy.
Which Should You Choose?
Choose Tesamorelin If:
- Visceral fat reduction is your primary goal — tesamorelin is the only peptide with proven VAT data
- You want the strongest evidence base — FDA-approved with Phase 3 trial results
- You have concerns about liver fat (MASH/NAFLD) — tesamorelin's hepatic fat reduction is significant
- You prefer a once-daily, single peptide protocol over a multi-peptide stack
- You're able to get a prescription or comfortable with research-grade sourcing
Choose CJC-1295/Ipamorelin If:
- General anti-aging is your goal — sleep, recovery, skin quality, energy
- You want the cleanest side effect profile — ipamorelin produces GH release without cortisol/prolactin/appetite effects
- Sleep improvement is a priority — the nighttime GH pulse enhancement is one of the most consistently reported benefits
- Cost is a factor — CJC-1295/ipamorelin is generally less expensive than tesamorelin
- You want a gradual, moderate GH elevation rather than maximum potency
Stack Tesamorelin + Ipamorelin If:
- You want maximum GH release through both GHRH and ghrelin pathways simultaneously
- You're targeting visceral fat + anti-aging benefits together
- Budget allows for a premium protocol
- Pre-blended tesamorelin/ipamorelin formulations (e.g., 10mg/3mg) make this convenient as a single injection
Dosing Comparison
Tesamorelin
- FDA-approved dose: 2 mg subcutaneously once daily (original Egrifta SV); 1.28 mg (updated Egrifta WR formulation)
- Off-label protocol: 1-2 mg once daily
- Timing: Bedtime on an empty stomach (at least 2-3 hours after last meal) — carbohydrates blunt the GH response
- Cycle: 8-12 weeks, reassess with body composition measurements
- Monitoring: IGF-1 levels, fasting glucose, lipid panel
CJC-1295/Ipamorelin
- CJC-1295 (no DAC): 100 mcg per injection
- Ipamorelin: 100-200 mcg per injection
- Frequency: 1-3 times daily. Most common: once at bedtime. Advanced: morning + bedtime.
- Timing: Empty stomach, ideally bedtime to enhance the natural nighttime GH surge
- Cycle: 8-12 weeks on, 4 weeks off. Some protocols run continuously with monitoring.
Tesamorelin + Ipamorelin Stack
- Tesamorelin: 1-2 mg
- Ipamorelin: 100-200 mcg
- Frequency: Once daily at bedtime
- Available pre-blended (e.g., 10mg tesamorelin / 3mg ipamorelin vials)
Side Effects
Tesamorelin
- Injection site reactions — redness, swelling, itching (most common)
- Arthralgia — joint pain, typically mild
- Peripheral edema — fluid retention in hands/feet
- Paresthesia — numbness or tingling
- Blood glucose — may increase; monitor if diabetic/prediabetic
- Contraindicated with active malignancy — GH can promote tumor growth
CJC-1295/Ipamorelin
- Headache — mild, typically early in use
- Flushing or warmth — occasionally after injection
- Injection site irritation — mild
- Water retention — mild, usually transient
- No cortisol or prolactin increase — ipamorelin is selective
- No appetite increase — unlike GHRP-6
Both: Monitor IGF-1 levels periodically to ensure they remain within normal range. Avoid use with active cancer.
Frequently Asked Questions
What is the difference between tesamorelin and CJC-1295/ipamorelin?
Tesamorelin is an FDA-approved GHRH analog that produces strong, pulsatile GH release and has proven visceral fat reduction in Phase 3 trials. CJC-1295/ipamorelin is a research peptide stack combining a GHRH analog (CJC-1295) with a ghrelin mimetic (ipamorelin) to stimulate GH through two complementary pathways. Tesamorelin has stronger clinical evidence; CJC-1295/ipamorelin is more commonly used for general anti-aging.
Is tesamorelin better than CJC-1295/ipamorelin for fat loss?
For visceral fat specifically, yes. Tesamorelin is the only peptide with FDA-level evidence for visceral fat reduction — 15-18% reduction over 26 weeks in Phase 3 trials. CJC-1295/ipamorelin may improve body composition through sustained GH elevation, but lacks the targeted visceral fat data that tesamorelin has.
Can you take tesamorelin and ipamorelin together?
Yes. Tesamorelin and ipamorelin are one of the most popular peptide stacks in anti-aging medicine. They work through complementary pathways — tesamorelin stimulates GH release via GHRH receptors while ipamorelin stimulates it via ghrelin receptors. The combination produces stronger GH pulses than either alone. Pre-blended tesamorelin/ipamorelin formulations are widely available.
Which growth hormone peptide has the least side effects?
Ipamorelin has the cleanest side effect profile of any GH secretagogue. Unlike GHRP-6 or GHRP-2, it stimulates GH release without increasing cortisol, prolactin, or appetite. Tesamorelin is also well-tolerated, with injection site reactions being the most common side effect in clinical trials.
Do I need a prescription for tesamorelin?
Tesamorelin is FDA-approved by prescription (Egrifta/Egrifta WR) for HIV-associated lipodystrophy. For off-label use (visceral fat reduction, anti-aging), it is available from peptide suppliers as a research peptide, often in combination with ipamorelin.
Sources
-
Falutz, J., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. (LIPO-008)
-
Falutz, J., et al. (2010). Effects of tesamorelin on body composition and metabolic parameters in HIV-associated lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. (LIPO-011)
-
Friedman, S.D., et al. (2013). Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 70(7), 883-890.
-
Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
-
Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
-
Stanley, T.L., et al. (2014). Effects of tesamorelin on hepatic fat and metabolic markers. Journal of Clinical Endocrinology & Metabolism, 99(5), 1831-1837.